Please provide your email address to receive an email when new articles are posted on . “The entire Neurotech family mourns this loss,” the company said in a statement. “On behalf of the board of ...
CUMBERLAND, R.I., April 21, 2025--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the ...
CUMBERLAND, R.I., August 11, 2025--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the ...
Neurotech Pharmaceuticals, Inc., a clinical stage biotech company, today announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two ...
LEESBURG, Va.--(BUSINESS WIRE)--Theragen LLC, a privately owned medical device company, announced today the acquisition of Neurotech North America, a manufacturer of premier non-invasive stimulation ...
Dublin, Feb. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurotech Devices: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering. In this report, the market is segmented based on ...
Protein therapies for the eye must be dosed as frequent injections. Gene therapy offers one-time treatment, but must also be administered by injection. Neurotech Pharmaceuticals’ gene therapy comes in ...
Leesburg-based Theragen LLC, a privately owned medical device company, has acquired Neurotech North America, a manufacturer of noninvasive stimulation products for orthopedic and spinal indications.
Neurotech’s Encelto is surgically implanted and delivers genetically modified cell therapy to the eye Neurotech Pharmaceuticals Inc.’s research efforts are paying off. The biotech company, focused on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback